OncLive TV

Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer.

Eunice Wang, MD, discusses how the continued development of targeted therapies could improve the future treatment paradigm in acute myeloid leukemia.

Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.

Coral O. Omene, MD, PhD, discusses the importance of a multidisciplinary, patient-focused approach to mitigating disparities in the care of patients with breast cancer.

David R. Wise, MD, PhD, discusses changes in the optimal use of intensified treatment regimens in patients with metastatic hormone-sensitive prostate cancer.

Joshua G. Cohen, MD, FACOG, FACS, discusses key trials supporting the use of PARP inhibitor maintenance therapy in upfront setting in ovarian cancer.

Richard Kim, MD, discusses the investigation of RLY-4008 for the treatment of patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Ann-Kathrin Eisfeld, MD, discusses factors to consider when deciding whether to start treatment right away or wait for molecular testing results in patients with acute myeloid leukemia.

Sarah Goldberg, MD, MPH, discusses ongoing investigations with antibody-drug conjugates and bispecific antibodies in patients with non–small cell lung cancer harboring EGFR mutations.

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.

Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Andrew Katims, MD, MPH, discusses research characterizing immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing

Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.

James Harding, MD, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract cancers.

Dana B Cardin, MD, MSCI, discusses the rationale for exploring KRAS as a therapeutic target in pancreatic cancer.

Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.

Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.

Brian C. Grieb, MD, PhD, emphasizes the importance of investigating agents that target the MYC oncogene, as well as supportive cofactors, in colorectal cancer and other tumor types.

Marilena Tauro, PhD, discusses next steps planned for the development of novel autophagy inhibitory strategies to combat chemotherapy resistance in relapsed/refractory multiple myeloma.

Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.